GH Research (GHRS) Other Non Operating Income (2021 - 2025)
GH Research's (GHRS) quarterly Other Non Operating Income came in at $2.6 million in Q4 2025, down 37.71% year-on-year from $4.1 million in Q4 2024, and up 1.38% quarter-over-quarter from $2.5 million in Q3 2025.
GH Research (GHRS) Other Non Operating Income (2021 - 2025) Analysis & Trends
GH Research's Other Non Operating Income history runs 5 years deep, the most recent figure standing at $2.6 million for Q4 2025.
- On a quarterly basis, Other Non Operating Income fell 37.71% year-over-year to $2.6 million in Q4 2025; TTM through Dec 2025 was $12.5 million, a 9.77% increase from a year earlier, with the FY2025 full-year figure at $12.5 million, up 9.77% from the prior year.
- Other Non Operating Income climbed to $2.6 million in Q4 2025 per GHRS's latest filing, from $2.5 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $7.1 million in Q2 2022 and bottomed at -$8.3 million in Q4 2023.
- The 5-year median for Other Non Operating Income is $2.5 million (2021), against an average of $1.7 million.
- Biggest YoY gain for Other Non Operating Income was 25022.22% in 2022; the steepest drop was 428.54% in 2022.
- Year by year, Other Non Operating Income stood at $2.5 million in 2021, then tumbled by 428.54% to -$8.3 million in 2022, then fell by 0.43% to -$8.3 million in 2023, then surged by 149.62% to $4.1 million in 2024, then tumbled by 37.71% to $2.6 million in 2025.
- Per Business Quant, the three latest GHRS Other Non Operating Income figures stand at $2.6 million (Q4 2025), $2.5 million (Q3 2025), and $5.4 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | GH Research | 1.69 Bn | 1.69 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.58 Mn |
| Sep 30, 2025 | 2.55 Mn |
| Jun 30, 2025 | 5.42 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 4.14 Mn |
| Sep 30, 2024 | 507,000.00 |
| Jun 30, 2024 | 2.84 Mn |
| Mar 31, 2024 | 3.86 Mn |
| Dec 31, 2023 | -8.35 Mn |
| Sep 30, 2023 | 4.07 Mn |
| Jun 30, 2023 | 2.20 Mn |
| Mar 31, 2023 | -1.64 Mn |
| Dec 31, 2022 | -8.31 Mn |
| Sep 30, 2022 | 6.19 Mn |
| Jun 30, 2022 | 7.08 Mn |
| Mar 31, 2022 | 2.24 Mn |
| Dec 31, 2021 | 2.53 Mn |
| Sep 30, 2021 | 2.83 Mn |
| Jun 30, 2021 | 554,000.00 |
| Mar 31, 2021 | -9,000.00 |